| Name | APX-115 |
| Description | APX-115 (Ewha-18278) (Ewha-18278) is a potent, orally active pan NADPH oxidase (Nox) inhibitor (Kis: 1.08 μM, 0.57 μM, and 0.63 μM for Nox1, Nox2, and Nox4). APX-115 effectively prevents kidney injury. |
| In vitro | In the mouse podocyte cell line, APX-115 (5 μM; 60 min) almost completely suppresses high glucose-induced proinflammatory and profibrotic molecule expression. In the kidney, APX-115 attenuates Nox gene upregulation and protein expression while improving inflammatory and fibrotic processes [2]. |
| In vivo | APX-115 treatment decreases the urinary excretion of albumin and plasma creatinine levels. APX-115 (oral gavage; 60 mg/kg/day; for 12 weeks) significantly improves insulin resistance in diabetic mice[1]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | DMSO : 90 mg/mL (285 mM), Sonication is recommended.
|
| Keywords | NOX4 | Nox4 | Nox2 | NOX2 | NOX1 | Nox1 | NADPHoxidase | APX-115 | APX115 | APX 115 |
| Inhibitors Related | GLX351322 | APX-115 free base | NoxA1ds acetate(1435893-78-9 free base) | NecroX-7 | Ketoconazole | Aucuparin | Protosappanin A | Phox-I2 | ML-090 | GKT136901 | Setanaxib | VAS 3947 |
| Related Compound Libraries | Failed Clinical Trials Compound Library | Bioactive Compound Library | Anti-Diabetic Compound Library | Anti-Viral Compound Library | Drug Repurposing Compound Library | Inhibitor Library | Mitochondria-Targeted Compound Library | Orally Active Compound Library | Immunology/Inflammation Compound Library | Anti-Aging Compound Library | Bioactive Compounds Library Max | Anti-Infection Compound Library |